Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice

References

• Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, et al. Human infection with a novel avian-origin influenza a (H7N9) virus. N Engl J Med [Internet]. 2013 [accessed 2021 Dec 28];368(20):1–10. doi:10.1056/NEJMOA1304459. Cited: in: PMID: 23577628.
   PubMed Web of Science ®Google Scholar
• Qi W, Jia W, Liu D, Li J, Bi Y, Xie S, Li B, Hu T, Du Y, Xing L, et al. Emergence and adaptation of a novel highly pathogenic H7N9 influenza virus in birds and humans from a 2013 human-infecting low-pathogenic ancestor. J Virol [Internet]. 2018 [accessed 2021 Dec 28];92(2). doi:10.1128/JVI.00921-17. Cited: in: PMID: 29070694.
   Web of Science ®Google Scholar
• Wang X, Wu P, Pei Y, Tsang TK, Gu D, Wang W, Zhang J, Horby PW, Uyeki TM, Cowling BJ, et al. Assessment of human-to-human transmissibility of avian influenza A(H7N9) virus across 5 waves by analyzing clusters of case patients in mainland China, 2013–2017. Clin Infect Dis [Internet]. 2019 [accessed 2021 Dec 28];68(4):623–31. doi:10.1093/CID/CIY541. Cited: in: PMID: 29961834.
   PubMed Web of Science ®Google Scholar
• Wang X, Jiang H, Wu P, Uyeki TM, Feng L, Lai S, Wang L, Huo X, Xu K, Chen E, et al. Epidemiology of avian influenza a H7N9 virus in human beings across five epidemics in mainland China, 2013–17: an epidemiological study of laboratory-confirmed case series. Lancet Infect Dis [Internet]. 2017 [accessed 2021 Dec 28];17(8):822–32. doi:10.1016/S1473-3099(17)30323-7. Cited: in: PMID: 28583578.
   PubMed Web of Science ®Google Scholar
• WHO. WHO zoonotic influenza viruses: antigenic and genetic characteristics and development of candidate vaccine viruses for pandemic preparedness. Wkly Epidemiol Rec. 2017;92(12):129–44.
   PubMedGoogle Scholar
• Kile JC, Ren R, Liu L, Greene CM, Roguski K, Iuliano AD, Jang Y, Jones J, Thor S, Song Y, et al. Update: increase in human infections with novel Asian lineage avian influenza A(H7N9) viruses during the fifth epidemic — China, october 1, 2016–august 7, 2017. MMWR Morb Mortal Wkly Rep [Internet]. 2017 [accessed 2021 Dec 28];66(35):928–32. doi:10.15585/MMWR.MM6635A2. Cited: in: PMID: 28880856.
   PubMed Web of Science ®Google Scholar
• Su S, Gu M, Liu D, Cui J, Gao GF, Zhou J, Liu XE. Evolution, and pathogenesis of H7N9 influenza viruses in five epidemic waves since 2013 in China. Trends Microbiol [Internet]. 2017 [accessed 2021 Dec 28];25(9):713–28. doi:10.1016/J.TIM.2017.06.008. Cited: in: PMID: 28734617.
   PubMed Web of Science ®Google Scholar
• Burke SA, Trock SC. Use of influenza risk assessment tool for prepandemic preparedness. Emerg Infect Dis [Internet]. 2018 [accessed 2021 Dec 28];24(3):471–77. doi:10.3201/EID2403.171852. Cited: in: PMID: 29460739.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang D, Gao R, Zhao B, Song J, Qi X, Zhang Y, Shi Y, Yang L, Zhu W, et al. Biological features of novel avian influenza a (H7N9) virus. Nature [Internet]. 2013 [accessed 2021 Dec 28];499(7459):500–03. doi:10.1038/NATURE12379. Cited: in: PMID: 23823727.
   PubMed Web of Science ®Google Scholar
• Guo L, Zhang X, Ren L, Yu X, Chen L, Zhou H, Gao X, Teng Z, Li J, Hu J, et al. Human antibody responses to avian influenza A(H7N9) virus, 2013. Emerg Infect Dis [Internet]. 2014 [accessed 2021 Dec 28];20(2):192–200. doi:10.3201/EID2002.131094. Cited: in: PMID: 24447423.
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, Dickey M, Stapleton JT, Edupuganti S, Spearman P, et al. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. Jama [Internet]. 2014 [accessed 2021 Dec 28];312(14):1409–19. doi:10.1001/JAMA.2014.12854. Cited: in: PMID: 25291577.
   PubMed Web of Science ®Google Scholar
• Fries LF, Smith GE, Glenn GM. A recombinant viruslike particle influenza a (H7N9) vaccine. N Engl J Med [Internet]. 2013 [accessed 2021 Dec 28];369(26):2564–66. doi:10.1056/NEJMC1313186. Cited: in: PMID: 24224560.
   PubMed Web of Science ®Google Scholar
• de Groot AS, Ardito M, Terry F, Levitz L, Ross T, Moise L, Martin W. Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design. Hum Vaccin Immunother [Internet]. 2013 [accessed 2021 Dec 28];9(5):950–56. doi:10.4161/HV.24939. Cited: in: PMID: 23807079.
   PubMed Web of Science ®Google Scholar
• de Groot AS, Moise L, Liu R, Gutierrez AH, Terry F, Koita OA, Ross TM, Martin W. Cross-Conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design. Hum Vaccin Immunother [Internet]. 2014 [accessed 2021 Dec 28];10(2):256–62. doi:10.4161/HV.28135. Cited: in: PMID: 24525618.
   PubMed Web of Science ®Google Scholar
• Liu R, Moise L, Tassone R, Gutierrez AH, Terry FE, Sangare K, Ardito MT, Martin WD, de Groot AS. H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance. Hum Vaccin Immunother [Internet]. 2015 [accessed 2021 Dec 28];11(9):2241–52. doi:10.1080/21645515.2015.1052197. Cited: in: PMID: 26090577.
   PubMed Web of Science ®Google Scholar
• Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, Rawal S, Wang YH, Lim H, Reynolds JM, Zhou XH, et al. Follicular regulatory T cells expressing foxp3 and bcl-6 suppress germinal center reactions. Nat Med [Internet]. 2011 [accessed 2021 Dec 29];17(8):983–88. doi:10.1038/NM.2426. Cited: in: PMID: 21785430.
   PubMed Web of Science ®Google Scholar
• Wada Y, Nithichanon A, Nobusawa E, Moise L, Martin WD, Yamamoto N, Terahara K, Hagiwara H, Odagiri T, Tashiro M, et al. A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines. Sci Rep [Internet]. 2017 [accessed 2021 Dec 28];7(1). doi:10.1038/S41598-017-01372-5. Cited: in: PMID: 28455520.
   Google Scholar
• Jang H, Meyers LM, Boyle C, de Groot AS, Moise L, Ross TM. Immune-Engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge. Hum Vaccin Immunother [Internet]. 2020 [accessed 2021 Dec 23];16(9):2042–50. doi:10.1080/21645515.2020.1793711. Cited: in: PMID: 32783766.
   PubMed Web of Science ®Google Scholar
• Carter DM, Darby CA, Lefoley BC, Crevar CJ, Alefantis T, Oomen R, Anderson SF, Strugnell T, Cortés-Garcia G, Vogel TU, et al. Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses. J Virol [Internet]. 2016 [accessed 2021 Dec 23];90(9):4720–34. doi:10.1128/JVI.03152-15. Cited: in: PMID: 26912624.
   PubMed Web of Science ®Google Scholar
• Huang Y, Owino SO, Crevar CJ, Carter DM, Ross TM. N-Linked glycans and K147 residue on hemagglutinin synergize to elicit broadly reactive H1N1 influenza virus antibodies. 2020. doi:10.1128/JVI.01432-19.
   Google Scholar
• Tan GS, Lee PS, Hoffman RMB, Mazel-Sanchez B, Krammer F, Leon PE, Ward AB, Wilson IA, Palese P. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza a virus hemagglutinin. J Virol [Internet]. 2014 [accessed 2021 Dec 23];88(23):13580–92. doi:10.1128/JVI.02289-14. Cited: in: PMID: 25210195.
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HKB, Graham IL, Noah DL, He F, Hill H. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis [Internet]. 2008 [accessed 2021 Dec 28];197(5):667–75. doi:10.1086/527489. Cited: in: PMID: 18260764.
   PubMed Web of Science ®Google Scholar
• Keitel WA, Campbell JD, Treanor JJ, Walter EB, Patel SM, He F, Noah DL, Hill H. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I–II randomized clinical trial. J Infect Dis [Internet]. 2008 [accessed 2021 Dec 28];198(9):1309–16. doi:10.1086/592172. Cited: in: PMID: 18808338.
   PubMed Web of Science ®Google Scholar
• Eurosurveillance editorial team. Swedish medical products agency publishes report from a case inventory study on pandemrix vaccination and development of narcolepsy with cataplexy. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Internet].2011 [accessed 2021 Dec 28];16. doi:10.2807/ESE.16.26.19904-EN. Cited: in: PMID: 21745441.
   Google Scholar
• Partinen M, Saarenpää-Heikkilä O, Ilveskoski I, Hublin C, Linna M, Olsén P, Nokelainen P, Alén R, Wallden T, Espo M, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One [Internet]. 2012 [accessed 2021 Dec 28];7(3):e33723. doi:10.1371/JOURNAL.PONE.0033723. Cited: in: PMID: 22470463.
   PubMed Web of Science ®Google Scholar
• Jansen JM, Gerlach T, Elbahesh H, Rimmelzwaan GF, Saletti G. Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination. J Clin Virol [Internet]. 2019 [accessed 2021 Dec 28];119:44–52. doi:10.1016/J.JCV.2019.08.009. Cited: in: PMID: 31491709.
   PubMed Web of Science ®Google Scholar
• Spensieri F, Borgogni E, Zedda L, Bardelli M, Buricchi F, Volpini G, Fragapane E, Tavarini S, Finco O, Rappuoli R, et al. Human circulating influenza-CD4+ICOS1+IL-21+T cells expand after vaccination, exert helper function, and predict antibody responses. Proc Natl Acad Sci USA [Internet]. 2013 [accessed 2021 Dec 28];110(35):14330–35. doi:10.1073/PNAS.1311998110. Cited: in: PMID: 23940329.
   PubMed Web of Science ®Google Scholar
• Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol [Internet]. 2011 [accessed 2021 Dec 28];29(1):621–63. doi:10.1146/ANNUREV-IMMUNOL-031210-101400. Cited: in: PMID: 21314428.
   PubMed Web of Science ®Google Scholar
• Alam S, Knowlden ZAG, Sangster MY, Sant AJ. CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection. J Virol [Internet]. 2014 [accessed 2021 Dec 28];88(1):314–24. doi:10.1128/JVI.02077-13. Cited: in: PMID: 24155379.
   PubMed Web of Science ®Google Scholar
• Nayak JL, Fitzgerald TF, Richards KA, Yang H, Treanor JJ, Sant AJ. CD4+ T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A(H1N1) virus subtype H1N1 vaccine. J Infect Dis [Internet]. 2013 [accessed 2021 Dec 28];207(2):297–305. doi:10.1093/INFDIS/JIS684. Cited: in: PMID: 23148285.
   PubMed Web of Science ®Google Scholar
• Nayak JL, Richards KA, Yang H, Treanor JJ, Sant AJ. Effect of influenza A(H5N1) vaccine prepandemic priming on CD4+ T-cell responses. J Infect Dis [Internet]. 2015 [accessed 2021 Dec 28];211(9):1408–17. doi:10.1093/INFDIS/JIU616. Cited: in: PMID: 25378637.
   PubMed Web of Science ®Google Scholar
• Das SR, Hensley SE, Ince WL, Brooke CB, Subba A, Delboy MG, Russ G, Gibbs JS, Bennink JR, Yewdell JW. Defining influenza a virus hemagglutinin antigenic drift by sequential monoclonal antibody selection. Cell Host Microbe [Internet]. 2013 [accessed 2021 Dec 28];13(3):314–23. doi:10.1016/J.CHOM.2013.02.008. Cited: in: PMID: 23498956.
   PubMed Web of Science ®Google Scholar
• Thyagarajan B, Bloom JD. The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin. Elife [Internet]. 2014 [accessed 2021 Dec 28];3. doi:10.7554/ELIFE.03300. Cited: in: PMID: 25006036.
   PubMed Web of Science ®Google Scholar
• Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol [Internet]. 2009 [accessed 2021 Dec 28];333:43–82. doi:10.1007/978-3-540-92165-3_3. Cited: in: PMID: 19768400.
   PubMedGoogle Scholar
• Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, et al. Response to a monovalent 2009 influenza a (H1N1) vaccine. N Engl J Med [Internet]. 2009 [accessed 2021 Dec 28];361(25):2405–13. doi:10.1056/NEJMOA0907413. Cited: in: PMID: 19745216.
   PubMed Web of Science ®Google Scholar
• Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. Trial of 2009 influenza a (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med [Internet]. 2009 [accessed 2020 Dec 23];361(25):2424–35. doi:10.1056/nejmoa0907650.
   PubMed Web of Science ®Google Scholar
• Weber CA, Mehta PJ, Ardito M, Moise L, Martin B, de Groot AS. T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv Drug Deliv Rev [Internet]. 2009 [accessed 2021 Dec 28];61(11):965–76. doi:10.1016/J.ADDR.2009.07.001. Cited: in: PMID: 19619593.
   PubMed Web of Science ®Google Scholar
• Posch PE, Hastings AE, Rosen-Bronson S, Richert JR, Hurley CK. The relative importance of individual DR binding motif positions as defined by peptide anchor analysis of influenza hemagglutinin peptide 306-318 and human myelin basic protein peptide 152-165 binding to several DR molecules: definition of a common extended DR binding motif. Eur J Immunol [Internet]. 1996 [accessed 2021 Dec 28];26:1884–91. doi:10.1002/EJI.1830260832. Cited: in: PMID: 8765035.
   PubMed Web of Science ®Google Scholar
• DiPiazza AT, Fan S, Rattan A, DeDiego ML, Chaves F, Neumann G, Kawaoka Y, Sant AJ. A novel vaccine strategy to overcome poor immunogenicity of avian influenza vaccines through mobilization of memory CD4 T cells established by seasonal influenza. J Immunol [Internet]. 2019 [accessed 2021 Dec 28];203(6):1502–08. doi:10.4049/JIMMUNOL.1900819. Cited: in: PMID: 31399519.
   PubMed Web of Science ®Google Scholar